Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Saturday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Up 1.7 %

Shares of Check-Cap stock opened at $1.82 on Friday. The stock has a market capitalization of $10.65 million, a price-to-earnings ratio of -0.61 and a beta of 0.39. Check-Cap has a 1-year low of $1.76 and a 1-year high of $4.63. The firm’s 50-day moving average price is $1.93 and its two-hundred day moving average price is $2.11.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.